Lipid-lowering agents and new onset diabetes mellitus
- 20 May 2010
- journal article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 11 (12) , 1965-1970
Abstract
Statin treatment (and possibly niacin when given alone or in combination with statins) appears to be associated with a slightly increased risk of new onset diabetes mellitus (NODM). However, statin induced cardiovascular disease (CVD) risk reduction is greater in patients with DM than in non-diabetic patients in several survival studies. Thus, statin treatment outweighs any potential increase in CVD risk related to NODM and in high-risk Caucasian patients present clinical practice should not change. However, the risk/benefit ratio of treatment might not be as favourable in subjects with propensity to develop DM such as the elderly and in subjects of Asian ethnicity. Colesevelam was shown to improve both glycaemic control and lipid profile in inadequately controlled T2DM and might reduce the risk for NODM. There are no data on the incidence of NODM in fibrate-treated non-diabetic patients. Prospective studies are needed to clarify these issues.Keywords
This publication has 52 references indexed in Scilit:
- The relative importance of modifiable potential risk factors of type 2 diabetes: a meta-analysis of two cohortsEuropean Journal of Epidemiology, 2009
- Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-AnalysisDiabetes Care, 2009
- Demographic Differences and Trends of Vitamin D Insufficiency in the US Population, 1988-2004Archives of internal medicine (1960), 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patientsAtherosclerosis, 2008
- Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic PatientsDiabetes Care, 2008
- Impact of New-Onset Diabetes Mellitus on Cardiac Outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial PopulationHypertension, 2007
- Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetesClinical and Experimental Medicine, 2006
- Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the wayDiabetologia, 2006
- Adverse Prognostic Significance of New Diabetes in Treated Hypertensive SubjectsHypertension, 2004